Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.
Novartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, as sales of a new class of injected drugs begin to mount.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl